Contents
pdf Download PDF
pdf Download XML
71 Views
17 Downloads
Share this article
Original Article | Volume 5 Issue 2 (None, 2019) | Pages 138 - 144
Comparative Evaluation of Hemodynamic Responses Following Induction With Propofol and Etomidate in Patients Undergoing Elective Surgery
1
Assistant Professor, Department of Anaesthesiology, at Fathima Institute of Medical Sciences, Kadapa
Under a Creative Commons license
Open Access
Received
Oct. 14, 2026
Revised
Oct. 21, 2026
Accepted
Nov. 6, 2026
Published
Nov. 25, 2026
Abstract
Background: Induction of general anaesthesia is frequently associated with changes in cardiovascular function, including hypotension, tachycardia, bradycardia, and fluctuations in mean arterial pressure. Propofol and etomidate are commonly used intravenous induction agents with different cardiovascular effects. Propofol provides rapid induction and recovery but may produce significant hypotension, whereas etomidate is generally associated with greater cardiovascular stability.Aim: To compare the hemodynamic responses following induction with propofol and etomidate in adult patients undergoing elective surgical procedures under general anaesthesia.Materials and Methods: A prospective, randomized, controlled study is proposed in the Department of Anaesthesiology, Mamata Medical College, Khammam. Adult patients aged 18–60 years belonging to American Society of Anesthesiologists (ASA) physical status I or II and scheduled for elective surgery under general anaesthesia will be enrolled after informed consent. Participants will be randomized to receive either propofol or etomidate for anaesthetic induction. Heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure will be recorded at baseline, following induction, immediately after endotracheal intubation, and at predetermined intervals. Drug-related complications will also be documented.Results: The primary outcome will be the difference between groups in maximum percentage reduction in mean arterial pressure during the induction period. Secondary outcomes will include heart rate variation, incidence of hypotension, vasopressor requirements, pain on injection, apnea, and myoclonus. Comparative analysis will be performed after recruitment and collection of patient-level observations.Conclusion: Comparative assessment of propofol and etomidate may help determine the relative cardiovascular effects of these intravenous induction agents. The findings may support evidence-based selection of induction agents in patients undergoing elective surgical procedures
Keywords
INTRODUCTION
Induction of general anaesthesia represents a critical phase of perioperative management during which rapid alterations in cardiovascular physiology may occur. Administration of intravenous anaesthetic agents, followed by airway manipulation and endotracheal intubation, can produce substantial fluctuations in systemic blood pressure and heart rate. These responses may be particularly important in patients with limited cardiovascular reserve, although clinically significant hemodynamic changes can also occur in otherwise healthy individuals. Selection of an appropriate induction agent is therefore an essential component of safe anaesthetic practice. Propofol is one of the most commonly administered intravenous agents for induction and maintenance of general anaesthesia. Its clinical advantages include rapid onset, smooth induction, favorable recovery characteristics, and antiemetic properties. Nevertheless, propofol frequently produces dose-dependent cardiovascular depression through reductions in systemic vascular resistance and alterations in cardiac performance. These physiological effects may result in hypotension, especially following administration of induction doses or in patients with reduced intravascular volume. In a prospective randomized study, Aggarwal et al. compared propofol and etomidate in 100 patients undergoing general anaesthesia and observed greater cardiovascular changes in the propofol group [1]. Etomidate is an imidazole-derived intravenous hypnotic agent characterized by rapid onset and relatively limited direct cardiovascular depression. It is often selected when preservation of hemodynamic stability is a major clinical consideration. Unlike propofol, etomidate generally produces smaller reductions in arterial blood pressure at conventional induction doses. However, its administration may be associated with myoclonus, pain on injection, postoperative nausea and vomiting, and transient suppression of adrenal steroid synthesis. Therefore, the selection of an induction agent requires consideration of both cardiovascular and noncardiovascular adverse effects. Comparative research has demonstrated differences in hemodynamic responses to these agents. Kaur et al. evaluated hemodynamic changes and myoclonus during induction with propofol and etomidate in a randomized controlled study. Their investigation highlighted the relevance of blood pressure stability and drug-related adverse effects when comparing induction agents [2]. Similarly, clinical research involving propofol, etomidate, and their combination demonstrated greater reductions in systemic hemodynamic parameters after propofol administration compared with etomidate-containing induction techniques [3]. The cardiovascular effects of induction agents may also depend on patient characteristics, anaesthetic technique, baseline hemodynamic status, and concurrent medications. Premedication, opioid administration, neuromuscular blockade, and airway instrumentation can modify the observed cardiovascular response. Consequently, standardization of the anaesthetic protocol is essential when comparing induction agents. In a randomized trial involving patients undergoing cardiac surgery, Hannam et al. reported that propofol produced a greater reduction in mean arterial pressure relative to etomidate, even though vasopressor administration was more frequent in the propofol group [4]. Although these findings support the hemodynamic advantages of etomidate in a particular clinical population, the results cannot be automatically generalized to all elective surgical patients. A large randomized clinical trial in older surgical patients subsequently demonstrated differences in intraoperative blood pressure-related outcomes between etomidate and propofol, while also emphasizing the importance of examining broader postoperative safety endpoints [5]. This reinforces the principle that improved short-term hemodynamic stability does not necessarily establish overall clinical superiority. Despite extensive use of both drugs, comparative evaluation remains relevant because of variations in surgical populations, anaesthetic practices, and institutional protocols. Furthermore, comprehensive assessment should include changes in heart rate, systolic and diastolic pressure, mean arterial pressure, and adverse events. The present study is therefore proposed to compare the hemodynamic responses following intravenous induction with propofol and etomidate among adult patients undergoing elective surgery at Mamata Medical College, Khammam.
MATERIALS AND METHODS
The proposed study will be a prospective, randomized, parallel-group controlled clinical trial conducted in the Department of Anaesthesiology, Mamata Medical College, Khammam, Telangana, India. Eligible adult patients scheduled for elective surgical procedures under general anaesthesia with endotracheal intubation will be recruited over a predefined study period after Institutional Ethics Committee approval. The study protocol will be prospectively registered in the Clinical Trials Registry–India before enrolment, as applicable. 2.2 Study population Patients aged 18–60 years belonging to ASA physical status I or II will be considered for participation. Only patients for whom either propofol or etomidate is clinically acceptable will be included. Inclusion criteria: Adults undergoing elective surgery requiring general anaesthesia and endotracheal intubation, ASA physical status I or II, and willingness to provide written informed consent. Exclusion criteria: Known hypersensitivity to either study drug, pregnancy, significant cardiovascular instability, uncontrolled hypertension, severe cardiac dysfunction, known adrenal insufficiency, anticipated difficult airway, and conditions requiring a particular induction technique. 2.3 Sample size and randomization The sample size will be estimated using the anticipated difference in maximum percentage reduction in mean arterial pressure between groups and its standard deviation from relevant published research. The calculation will use a two-sided significance level of 0.05 and statistical power of at least 80%, with adjustment for withdrawals. Participants will be allocated in a 1:1 ratio using a computer-generated randomization sequence. Allocation concealment will be maintained through sequentially numbered, opaque envelopes or an equivalent secure method. The anaesthesiologist administering the induction agent may not be blinded because of differences in drug appearance; however, a separate investigator recording hemodynamic variables and the statistician may remain blinded wherever feasible. 2.4 Pre-anaesthetic evaluation All enrolled patients will undergo routine preoperative evaluation, including clinical history, physical examination, airway assessment, and relevant investigations. Baseline heart rate, systolic blood pressure, diastolic blood pressure, oxygen saturation, and mean arterial pressure will be documented after an appropriate resting period. Patients will receive standard perioperative monitoring using electrocardiography, noninvasive blood pressure measurement, pulse oximetry, and capnography after airway placement. Intravenous access and routine preparation will be established before induction. 2.5 Anaesthetic induction Participants will be assigned to one of two groups: Group P: Intravenous propofol administered at a protocol-defined, weight-adjusted induction dose. Group E: Intravenous etomidate administered at a protocol-defined, weight-adjusted induction dose. Previous randomized research has employed propofol 2 mg/kg and etomidate 0.3 mg/kg for comparable investigations [1]. The final doses, administration rates, and any clinical adjustments will be approved within the institutional protocol and administered by qualified anaesthesiologists. Premedication, opioid administration, neuromuscular blockade, ventilation strategy, and anaesthetic maintenance will be standardized as far as clinically appropriate. Rescue interventions will remain available whenever required for patient safety. 2.6 Hemodynamic monitoring Hemodynamic variables will be recorded at the following predefined time points: • T0: Pre-induction baseline • T1: After induction, before laryngoscopy • T2: Immediately after endotracheal intubation • T3: One minute after intubation • T4: Three minutes after intubation • T5: Five minutes after intubation • T6: Ten minutes after intubation Heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure will be measured at each time point. The primary outcome will be maximum percentage reduction in mean arterial pressure from baseline to the lowest value during the predefined induction observation period. Secondary outcomes will include the incidence of hypotension, bradycardia, vasopressor administration, myoclonus, pain on injection, and apnea. 2.7 Statistical analysis Data will be analysed using appropriate statistical software. Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, and categorical variables as frequencies and percentages. The primary outcome will be compared using an appropriate independent-group test or regression model. Repeated hemodynamic measurements will be assessed using a linear mixed-effects model incorporating treatment group, time, and group-by-time interaction. Categorical complications will be compared using chi-square or Fisher's exact tests. Effect sizes and 95% confidence intervals will accompany p-values, with statistical significance defined at p<0.05 for the prespecified primary comparison.
RESULTS
The following tables constitute the planned results format. Actual study values must be entered after data collection and statistical analysis. Table 1. Baseline demographic and clinical characteristics Parameter Group P (Propofol) Group E (Etomidate) Number of patients Pending Pending Age, years (mean ± SD) Pending Pending Male, n (%) Pending Pending Female, n (%) Pending Pending BMI, kg/m² (mean ± SD) Pending Pending ASA physical status I, n (%) Pending Pending ASA physical status II, n (%) Pending Pending Duration of surgery, minutes Pending Pending Table 1 will describe the demographic and baseline clinical characteristics of participants receiving propofol or etomidate. These variables will be examined to assess whether randomization produced groups with similar baseline profiles. Any clinically meaningful imbalances will be considered during interpretation and, where appropriate, adjusted analyses. Table 2. Comparison of heart rate at different observation times Observation time Propofol group (beats/min) Etomidate group (beats/min) Between-group p-value T0 – Baseline Pending Pending Pending T1 – Post-induction Pending Pending Pending T2 – Immediately after intubation Pending Pending Pending T3 – One minute Pending Pending Pending T4 – Three minutes Pending Pending Pending T5 – Five minutes Pending Pending Pending T6 – Ten minutes Pending Pending Pending This table will evaluate heart rate variation following administration of both induction agents. Changes after induction may reflect direct drug effects, whereas increases following laryngoscopy and intubation may reflect sympathetic stimulation. Between-group comparisons should be interpreted alongside the overall repeated-measures analysis rather than relying exclusively on individual time-point p-values. Table 3. Comparison of mean arterial pressure Observation time Propofol group MAP (mmHg) Etomidate group MAP (mmHg) Between-group p-value T0 – Baseline Pending Pending Pending T1 – Post-induction Pending Pending Pending T2 – Immediately after intubation Pending Pending Pending T3 – One minute Pending Pending Pending T4 – Three minutes Pending Pending Pending T5 – Five minutes Pending Pending Pending T6 – Ten minutes Pending Pending Pending Mean arterial pressure will provide the principal measure of cardiovascular stability. Reductions following induction will be compared between the groups, and the maximum percentage fall from baseline will be calculated for each participant. The findings will indicate whether one induction regimen is associated with smaller early blood pressure reductions. Table 4. Changes in systolic and diastolic blood pressure Hemodynamic outcome Propofol group Etomidate group p-value Baseline systolic BP (mmHg) Pending Pending Pending Lowest systolic BP (mmHg) Pending Pending Pending Baseline diastolic BP (mmHg) Pending Pending Pending Lowest diastolic BP (mmHg) Pending Pending Pending Maximum MAP reduction (%) Pending Pending Pending Table 4 will quantify changes in systolic and diastolic pressure and summarize the primary outcome. A comparison of maximum percentage reduction will help distinguish the relative cardiovascular effects of the two induction agents independently of their baseline pressure values. Table 5. Incidence of adverse events Adverse event Propofol group n (%) Etomidate group n (%) p-value Hypotension Pending Pending Pending Bradycardia Pending Pending Pending Tachycardia Pending Pending Pending Pain on injection Pending Pending Pending Myoclonus Pending Pending Pending Apnea Pending Pending Pending Vasopressor requirement Pending Pending Pending Table 5 will document clinically relevant adverse effects observed during induction. Hypotension and bradycardia must be defined prospectively in the trial protocol. The evaluation of pain on injection, myoclonus, and apnea will provide additional information about tolerability beyond hemodynamic stability.
DISCUSSION
The choice of intravenous induction agent is an important determinant of cardiovascular responses during general anaesthesia. Propofol and etomidate have distinct pharmacodynamic characteristics, and their relative effects on systemic blood pressure and heart rate have been evaluated in several clinical investigations. The present study is designed to compare these agents among elective surgical patients, with particular emphasis on mean arterial pressure changes, heart rate variation, and adverse events. The actual magnitude of any between-group difference will require analysis of the institutional study data. Aggarwal et al. conducted a randomized study involving 100 ASA I and II patients undergoing general anaesthesia [1]. Patients received either propofol or etomidate for induction, and hemodynamic responses were recorded throughout induction and airway instrumentation. The researchers reported that etomidate was associated with comparatively limited hemodynamic changes, whereas propofol produced greater cardiovascular depression. Pain on injection was more frequent with propofol, while myoclonus occurred more frequently following etomidate. These observations demonstrate that comparisons between induction drugs should incorporate both physiological stability and adverse-effect profiles. Kaur et al. investigated hemodynamic responses and the incidence of myoclonus during induction with propofol and etomidate [2]. Their randomized controlled study contributed additional evidence concerning the balance between cardiovascular stability and induction-related complications. Differences in study populations, premedication practices, and definitions of hemodynamic instability are important when interpreting such comparative findings. In another prospective randomized trial, investigators compared propofol, etomidate, and an admixture of the two agents [3]. The study demonstrated a more pronounced reduction in systemic hemodynamic parameters following propofol induction than with etomidate-containing regimens. The combination approach also illustrated the possibility of modifying induction-related adverse effects through changes in drug selection. However, combination regimens cannot be assumed to offer improved clinical outcomes without careful consideration of dosing, patient selection, and additional pharmacological effects. Hannam et al. assessed the cardiovascular effects of propofol and etomidate in patients undergoing cardiac surgery [4]. Their study found that propofol produced a substantially greater reduction in mean arterial pressure over time compared with etomidate, despite greater vasopressor use. These results are clinically important because excessive reductions in arterial pressure may compromise organ perfusion, especially in patients with limited physiological reserve. Nevertheless, cardiac surgical patients differ substantially from healthier adults undergoing elective noncardiac procedures, which limits direct extrapolation. Evidence from a large randomized clinical trial involving older surgical patients has also highlighted that favorable blood pressure profiles do not necessarily correspond to differences in all major postoperative complications [5]. In that study, the incidence of intraoperative hypotension was lower in the etomidate group, while other postoperative safety outcomes required separate evaluation. This distinction is relevant because intraoperative hemodynamic stability represents only one dimension of anaesthetic safety. The proposed study will therefore assess both cardiovascular measurements and clinically meaningful adverse events. Standardization of premedication, airway management, and maintenance anaesthesia will help reduce variation associated with factors other than the induction agent. Repeated measurements will allow identification of the period during which each agent produces the greatest physiological changes. Several limitations should be considered. The proposed single-centre design may restrict generalizability, and a study restricted to ASA I and II patients may not adequately represent higher-risk surgical populations. Differences in individual responsiveness, airway manipulation, and rescue medication administration may influence measured outcomes. Furthermore, the short observation period will not establish long-term cardiovascular or postoperative safety. Despite these limitations, the proposed trial may provide useful evidence regarding induction practices in the local clinical setting. Interpretation should emphasize the size and precision of hemodynamic differences, adverse-event rates, and clinical significance rather than statistical significance alone.
CONCLUSION
The proposed randomized study will compare these agents using standardized measurements of heart rate, systolic and diastolic pressure, mean arterial pressure, and induction-related complications. The results may help guide selection of induction agents for patients undergoing elective surgery. A definitive conclusion about comparative safety and hemodynamic superiority in the Mamata Medical College study population will require verified clinical measurements and statistical analysis.
REFERENCES
1. Aggarwal S, Goyal VK, Chaturvedi SK, Mathur V, Baj B, Kumar A. A comparative study between propofol and etomidate in patients under general anesthesia. Braz J Anesthesiol. 2016;66(3):237-241. doi: 10.1016/j.bjane.2014.10.005. 2. Hannam JA, Mitchell SJ, Cumin D, Frampton C, Merry AF, Moore MR, et al. Haemodynamic profiles of etomidate vs propofol for induction of anaesthesia: a randomised controlled trial in patients undergoing cardiac surgery. Br J Anaesth. 2019;122(2):198-205. doi: 10.1016/j.bja.2018.09.027. 3. Kaur B, Grewal TK, Gupta P. Comparative evaluation of haemodynamic response during induction of general anaesthesia and incidence of myoclonus with etomidate and propofol: a randomised controlled trial. J Clin Diagn Res. 2018;12(10):UC13-UC16. doi: 10.7860/JCDR/2018/30183.12160. 4. Rathore VS, Singh S, Taank P, Khandelwal A, Kaushal A. Clinical analysis of propofol, etomidate and an admixture of etomidate and propofol for induction of general anaesthesia. Turk J Anaesthesiol Reanim. 2019;47(5):382-386. doi: 10.5152/TJAR.2019.53806. 5. Lu Z, Zheng H, Chen Z, Xu S, Chen S, Mi W, et al. Effect of etomidate vs propofol for total intravenous anesthesia on major postoperative complications in older patients: a randomized clinical trial. JAMA Surg. 2022;157(10):888-895. doi: 10.1001/jamasurg.2022.3338. 6. Giri SK, Mohapatra PS, Senapati LK, Mishra K. A comparison of hemodynamic changes between the use of etomidate and propofol as induction agents for anesthesia in daycare surgeries. Cureus. 2022;14(12):e32421. doi: 10.7759/cureus.32421. 7. Saini S, Bhardwaj M, Sharma A, Taxak S. A randomised controlled trial to study bispectral guided induction of general anaesthesia using propofol and etomidate infusion. Indian J Anaesth. 2020;64(Suppl 3):S180-S185. doi: 10.4103/ija.IJA_221_20. 8. Moningi S, Reddy GP, Nikhar SA, Chikkala R, Kulkarni DK, Ramachandran G. Comparison of the influence of low dose etomidate and propofol as priming dose on the incidence of etomidate induced myoclonus: a randomised, double-blind clinical trial. Braz J Anesthesiol. 2022;72(2):261-266. doi: 10.1016/j.bjane.2021.02.047. 9. Mehta D, Palta S, Gupta N, Saroa R. Comparison of effect of etomidate with propofol on hemodynamics during modified electroconvulsive therapy. J Anaesthesiol Clin Pharmacol. 2022;38(1):104-110. doi: 10.4103/joacp.JOACP_185_20. 10. Wan C, Hanson AC, Schulte PJ, Dong Y, Bauer PR. Propofol, ketamine, and etomidate as induction agents for intubation and outcomes in critically ill patients: a retrospective cohort study. Crit Care Explor. 2021;3(5):e0435. doi: 10.1097/CCE.0000000000000435. 11. Shah J, Patel I, Guha A. Comparative study of propofol vs etomidate as an induction agent to evaluate hemodynamic changes during induction of anesthesia in controlled hypertensive patients. Anaesth Pain Intensive Care. 2018;22(3):361-367. Available from: Journal article. 12. Shivanna P. Comparision of induction characteristics and hemodynamic parameters of propofol versus etomidate in patients undergoing surgeries under general anaesthesia, a bispectral index guided study. Int J Innov Res Med Sci. 2017;2(11):1458-1467. doi: 10.23958/ijirms/vol02-i11/02. 13. Chen B, Pang QY, An R, Liu HL. A systematic review of risk factors for postinduction hypotension in surgical patients undergoing general anesthesia. Eur Rev Med Pharmacol Sci. 2021;25(22):7044-7050. doi: 10.26355/eurrev_202111_27255. 14. Yildirim SA, Dogan L, Sarikaya ZT, Ulugol H, Gucyetmez B, Toraman F. Hypotension after anesthesia induction: target-controlled infusion versus manual anesthesia induction of propofol. J Clin Med. 2023;12(16):5280. doi: 10.3390/jcm12165280. 15. Jor O, Maca J, Koutna J, Gemrotova M, Vymazal T, Litschmannova M, et al. Hypotension after induction of general anesthesia: occurrence, risk factors, and therapy. A prospective multicentre observational study. J Anesth. 2018;32(5):673-680. doi: 10.1007/s00540-018-2532-6.
Recommended Articles
Research Article
Perinatal Outcome In Neonates Born To High Risk Pregnancies –A Cross Sectional Observational Study
...
Published: 19/11/2026
Research Article
Adenoidectomy and Endoscopic Myringotomy with and without ventilation tube insertion for Treatment of Otitis Media with Effusion in 6-12 years old Children.
...
Published: 30/09/2026
Research Article
Clinico-Aetiological Profile And Short-Term Outcomes Of Children Aged 1 Month To 18 Years Presenting With Seizure At A Tertiary Care Centre
Published: 19/11/2026
Research Article
Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss
...
Published: 19/11/2026
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice